Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2011 Jun;20(6):1156-70.
doi: 10.1158/1055-9965.EPI-11-0017. Epub 2011 Apr 14.

Lower risk in parous women suggests that hormonal factors are important in bladder cancer etiology

Carol A Davis-Dao  1 , Katherine D Henderson, Jane Sullivan-Halley, Huiyan Ma, Dee West, Yong-Bing Xiang, Manuela Gago-Dominguez, Mariana C Stern, J Esteban Castelao, David V Conti, Malcolm C Pike, Leslie Bernstein, Victoria K Cortessis
Affiliations
Comparative Study

Lower risk in parous women suggests that hormonal factors are important in bladder cancer etiology

Carol A Davis-Dao et al. Cancer Epidemiol Biomarkers Prev. 2011 Jun.

Abstract

Background: Urinary bladder cancer is two to four times more common among men than among women, a difference in risk not fully explained by established risk factors. Our objective was to determine whether hormonal and reproductive factors are involved in female bladder cancer.

Methods: We analyzed data from two population-based studies: the Los Angeles-Shanghai Bladder Cancer Study, with 349 female case-control pairs enrolled in Los Angeles and 131 female cases and 138 frequency-matched controls enrolled in Shanghai, and the California Teachers Study (CTS), a cohort of 120,857 women with 196 incident cases of bladder urothelial carcinoma diagnosed between 1995 and 2005. We also conducted a meta-analysis summarizing associations from our primary analyses together with published results.

Results: In primary data analyses, parous women experienced at least 30% reduced risk of developing bladder cancer compared with nulliparous women (Shanghai: OR = 0.38, 95% CI: 0.13-1.10; CTS: RR = 0.69, 95% CI: 0.50-0.95) consistent with results of a meta-analysis of nine studies (summary RR = 0.73, 95% CI: 0.63-0.85). The CTS, which queried formulation of menopausal hormone therapy (HT), revealed a protective effect for use of combined estrogen and progestin compared with no HT (RR = 0.60, 95% CI: 0.37-0.98). Meta-analysis of three studies provided a similar effect estimate (summary RR = 0.65, 95% CI: 0.48-0.88).

Conclusions: A consistent pattern of reduced bladder cancer risk was found among parous women and those who used estrogen and progestin for HT.

Impact: These results suggest that more research is warranted to investigate hormonal and reproductive factors as possible contributors to bladder cancer risk.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Forrest plots displaying contributing data and results of meta-analyses relating parity to risk of bladder cancer: (A) among all women; (B) within strata of smoking history. Summary relative risk (SRR) top and bottom points of diamond; 95% CI of SRR, left and right points of diamond; stratum-specific SRR, open diamond; overall SRR, filled diamond. Individual study RR estimate and 95% CI, point and horizontal line; relative weight, box size.
Figure 2
Figure 2
Forrest plots displaying contributing data and results of meta-analyses relating history of exogenous hormone use to risk of bladder cancer, ever versus never use of: (A) oral contraceptives; (B) any menopausal hormone therapy (HT); (C) estrogen alone for HT; (D) estrogen plus progestin for HT. Summary relative risk (SRR), top and bottom points of diamond; 95% CI of SRR, left and right points of diamond; stratum-specific SRR, open diamond; overall SRR, filled diamond. Individual study RR estimate and 95% CI, point and horizontal line; relative weight, box size.
See this image and copyright information in PMC

References

    1. American Cancer Society. Cancer Facts and Figures 2010. Atlanta: American Cancer Society; 2010.
    1. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, et al. Epidemiology of urinary bladder cancer: from tumor development to patient’s death. World J Urol. 2007;25:285–295. - PubMed
    1. Report on Carcinogens. Eleventh Edition; U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program. 2005
    1. Castelao JE, Yuan J-M, Skipper PL, Tannenbaum SR, Gago-Dominguez M, Crowder JS, et al. Gender- and smoking-related bladder cancer risk. J Natl Cancer Instit. 2001;93:538–545. - PubMed
    1. Hartge P, Harvey EB, Linehan WM, Silverman DT, Sullivan JW, Hoover RN, et al. Unexplained excess risk of bladder cancer in men. J Natl Cancer Instit. 82. 1990:1636–1640. - PubMed

Publication types